Letter to the editor, Reply to: Lee and Matulonis: Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?

• CALLA (NCT03830866) is a randomized, international, double-blind, placebo-controlled study. • Immunotherapy-naïve patients with adenocarcinoma or cervical carcinoma are being enrolled. • CALLA is one of the largest trials in this patient population.

Detalles Bibliográficos
Autores principales: Monk, Bradley J., Mayadev, Jyoti, Nunes, Ana T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906726/
https://www.ncbi.nlm.nih.gov/pubmed/31867430
http://dx.doi.org/10.1016/j.gore.2019.100506
_version_ 1783478404643815424
author Monk, Bradley J.
Mayadev, Jyoti
Nunes, Ana T.
author_facet Monk, Bradley J.
Mayadev, Jyoti
Nunes, Ana T.
author_sort Monk, Bradley J.
collection PubMed
description • CALLA (NCT03830866) is a randomized, international, double-blind, placebo-controlled study. • Immunotherapy-naïve patients with adenocarcinoma or cervical carcinoma are being enrolled. • CALLA is one of the largest trials in this patient population.
format Online
Article
Text
id pubmed-6906726
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-69067262019-12-20 Letter to the editor, Reply to: Lee and Matulonis: Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy? Monk, Bradley J. Mayadev, Jyoti Nunes, Ana T. Gynecol Oncol Rep Correspondence • CALLA (NCT03830866) is a randomized, international, double-blind, placebo-controlled study. • Immunotherapy-naïve patients with adenocarcinoma or cervical carcinoma are being enrolled. • CALLA is one of the largest trials in this patient population. Elsevier 2019-10-10 /pmc/articles/PMC6906726/ /pubmed/31867430 http://dx.doi.org/10.1016/j.gore.2019.100506 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Correspondence
Monk, Bradley J.
Mayadev, Jyoti
Nunes, Ana T.
Letter to the editor, Reply to: Lee and Matulonis: Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?
title Letter to the editor, Reply to: Lee and Matulonis: Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?
title_full Letter to the editor, Reply to: Lee and Matulonis: Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?
title_fullStr Letter to the editor, Reply to: Lee and Matulonis: Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?
title_full_unstemmed Letter to the editor, Reply to: Lee and Matulonis: Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?
title_short Letter to the editor, Reply to: Lee and Matulonis: Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?
title_sort letter to the editor, reply to: lee and matulonis: immunotherapy and radiation combinatorial trials in gynecologic cancer: a potential synergy?
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906726/
https://www.ncbi.nlm.nih.gov/pubmed/31867430
http://dx.doi.org/10.1016/j.gore.2019.100506
work_keys_str_mv AT monkbradleyj lettertotheeditorreplytoleeandmatulonisimmunotherapyandradiationcombinatorialtrialsingynecologiccancerapotentialsynergy
AT mayadevjyoti lettertotheeditorreplytoleeandmatulonisimmunotherapyandradiationcombinatorialtrialsingynecologiccancerapotentialsynergy
AT nunesanat lettertotheeditorreplytoleeandmatulonisimmunotherapyandradiationcombinatorialtrialsingynecologiccancerapotentialsynergy

Ejemplares similares